Floseal hemostatic matrix (Baxter Healthcare Corp.) for hemostasis during nephrectomy
Record ID 32013000139
English
Authors' recommendations:
Approximately 65,000 Americans are diagnosed annually with renal cancer. Most patients (62%) have localized disease at diagnosis and are therefore potentially surgically curable. The 5-year relative survival is 91.1% for such patients. Treatment of early-stage kidney cancer emphasizes nephron-sparing surgery with partial nephrectomy (PN). Benign renal masses may also be treated with PN. Achieving hemostasis during PN is challenging. Suturing and coagulative methods may compromise the remaining renal tissue. Most urologic surgeons use hemostatic agents during PN, either alone or in combination with other methods.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=14212
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Nephrectomy
- Hemostasis, Surgical
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.